Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF)shares rose as much as 10% in Tuesday morning trading after the AIM-listed biopharmaceutical company secured its first national patent grant for POLB 001. This is the drug developer's lead candidate for preventing a serious side effect of cancer immunotherapy.